Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
DRAD's Cash to Debt is ranked higher than
97% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. DRAD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DRAD' s 10-Year Cash to Debt Range
Min: 0.56  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.78
DRAD's Equity to Asset is ranked higher than
75% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. DRAD: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
DRAD' s 10-Year Equity to Asset Range
Min: -1.99  Med: 0.81 Max: 0.84
Current: 0.78
-1.99
0.84
Interest Coverage 64.56
DRAD's Interest Coverage is ranked lower than
64% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. DRAD: 64.56 )
Ranked among companies with meaningful Interest Coverage only.
DRAD' s 10-Year Interest Coverage Range
Min: 0.66  Med: 10000.00 Max: 9999.99
Current: 64.56
0.66
9999.99
F-Score: 6
Z-Score: 2.80
M-Score: -2.37
WACC vs ROIC
7.91%
29.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 5.53
DRAD's Operating margin (%) is ranked higher than
58% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. DRAD: 5.53 )
Ranked among companies with meaningful Operating margin (%) only.
DRAD' s 10-Year Operating margin (%) Range
Min: -182.88  Med: -9.49 Max: 4.53
Current: 5.53
-182.88
4.53
Net-margin (%) 6.34
DRAD's Net-margin (%) is ranked higher than
66% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. DRAD: 6.34 )
Ranked among companies with meaningful Net-margin (%) only.
DRAD' s 10-Year Net-margin (%) Range
Min: -190.47  Med: -8.54 Max: 4.45
Current: 6.34
-190.47
4.45
ROE (%) 10.77
DRAD's ROE (%) is ranked higher than
72% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. DRAD: 10.77 )
Ranked among companies with meaningful ROE (%) only.
DRAD' s 10-Year ROE (%) Range
Min: -14.95  Med: -9.36 Max: 7.5
Current: 10.77
-14.95
7.5
ROA (%) 8.43
DRAD's ROA (%) is ranked higher than
79% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. DRAD: 8.43 )
Ranked among companies with meaningful ROA (%) only.
DRAD' s 10-Year ROA (%) Range
Min: -172.76  Med: -7.64 Max: 5.94
Current: 8.43
-172.76
5.94
ROC (Joel Greenblatt) (%) 39.56
DRAD's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. DRAD: 39.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DRAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -134.97  Med: -30.05 Max: 34.95
Current: 39.56
-134.97
34.95
Revenue Growth (3Y)(%) 1.50
DRAD's Revenue Growth (3Y)(%) is ranked lower than
56% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. DRAD: 1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DRAD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -90.7  Med: -6.70 Max: 35.4
Current: 1.5
-90.7
35.4
» DRAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

DRAD Guru Trades in Q3 2014

Jim Simons 1,007,133 sh (New)
Jim Simons 931,630 sh (+4.79%)
» More
Q4 2014

DRAD Guru Trades in Q4 2014

Jim Simons 1,007,133 sh (+8.10%)
» More
Q1 2015

DRAD Guru Trades in Q1 2015

Jim Simons 926,200 sh (-8.04%)
» More
Q2 2015

DRAD Guru Trades in Q2 2015

Jim Simons 926,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.64
DRAD's P/E(ttm) is ranked higher than
66% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. DRAD: 19.64 )
Ranked among companies with meaningful P/E(ttm) only.
DRAD' s 10-Year P/E(ttm) Range
Min: 15.36  Med: 29.69 Max: 202.11
Current: 19.64
15.36
202.11
PE(NRI) 19.50
DRAD's PE(NRI) is ranked higher than
66% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. DRAD: 19.50 )
Ranked among companies with meaningful PE(NRI) only.
DRAD' s 10-Year PE(NRI) Range
Min: 15.29  Med: 29.65 Max: 192
Current: 19.5
15.29
192
P/B 1.99
DRAD's P/B is ranked higher than
65% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. DRAD: 1.99 )
Ranked among companies with meaningful P/B only.
DRAD' s 10-Year P/B Range
Min: 0.19  Med: 1.20 Max: 2.86
Current: 1.99
0.19
2.86
P/S 1.27
DRAD's P/S is ranked higher than
72% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. DRAD: 1.27 )
Ranked among companies with meaningful P/S only.
DRAD' s 10-Year P/S Range
Min: 0.02  Med: 0.88 Max: 1.99
Current: 1.27
0.02
1.99
PFCF 18.75
DRAD's PFCF is ranked higher than
79% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 33.52 vs. DRAD: 18.75 )
Ranked among companies with meaningful PFCF only.
DRAD' s 10-Year PFCF Range
Min: 0.13  Med: 17.45 Max: 353
Current: 18.75
0.13
353
POCF 13.37
DRAD's POCF is ranked higher than
78% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 22.08 vs. DRAD: 13.37 )
Ranked among companies with meaningful POCF only.
DRAD' s 10-Year POCF Range
Min: 0.08  Med: 17.05 Max: 412
Current: 13.37
0.08
412
EV-to-EBIT 15.85
DRAD's EV-to-EBIT is ranked higher than
67% of the 159 Companies
in the Global Medical Devices industry.

( Industry Median: 21.34 vs. DRAD: 15.85 )
Ranked among companies with meaningful EV-to-EBIT only.
DRAD' s 10-Year EV-to-EBIT Range
Min: -128.3  Med: -2.40 Max: 293.9
Current: 15.85
-128.3
293.9
Current Ratio 3.64
DRAD's Current Ratio is ranked higher than
65% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. DRAD: 3.64 )
Ranked among companies with meaningful Current Ratio only.
DRAD' s 10-Year Current Ratio Range
Min: 1.03  Med: 4.62 Max: 5.53
Current: 3.64
1.03
5.53
Quick Ratio 3.21
DRAD's Quick Ratio is ranked higher than
69% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. DRAD: 3.21 )
Ranked among companies with meaningful Quick Ratio only.
DRAD' s 10-Year Quick Ratio Range
Min: 0.88  Med: 4.13 Max: 4.82
Current: 3.21
0.88
4.82
Days Inventory 33.25
DRAD's Days Inventory is ranked higher than
92% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. DRAD: 33.25 )
Ranked among companies with meaningful Days Inventory only.
DRAD' s 10-Year Days Inventory Range
Min: 31.58  Med: 42.06 Max: 54.41
Current: 33.25
31.58
54.41
Days Sales Outstanding 46.11
DRAD's Days Sales Outstanding is ranked higher than
83% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. DRAD: 46.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRAD' s 10-Year Days Sales Outstanding Range
Min: 38.23  Med: 42.92 Max: 79.15
Current: 46.11
38.23
79.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.32
DRAD's Dividend Yield is ranked higher than
91% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. DRAD: 5.32 )
Ranked among companies with meaningful Dividend Yield only.
DRAD' s 10-Year Dividend Yield Range
Min: 1.3  Med: 4.53 Max: 5.45
Current: 5.32
1.3
5.45
Dividend Payout 1.06
DRAD's Dividend Payout is ranked lower than
93% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. DRAD: 1.06 )
Ranked among companies with meaningful Dividend Payout only.
DRAD' s 10-Year Dividend Payout Range
Min: 0.83  Med: 1.24 Max: 1.28
Current: 1.06
0.83
1.28
Yield on cost (5-Year) 5.32
DRAD's Yield on cost (5-Year) is ranked higher than
87% of the 184 Companies
in the Global Medical Devices industry.

( Industry Median: 1.63 vs. DRAD: 5.32 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DRAD' s 10-Year Yield on cost (5-Year) Range
Min: 1.3  Med: 4.53 Max: 5.45
Current: 5.32
1.3
5.45
Share Buyback Rate 0.30
DRAD's Share Buyback Rate is ranked higher than
85% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: -4.20 vs. DRAD: 0.30 )
Ranked among companies with meaningful Share Buyback Rate only.
DRAD' s 10-Year Share Buyback Rate Range
Min: 0.3  Med: -0.95 Max: -1314
Current: 0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.47
DRAD's Price/Net Cash is ranked higher than
74% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 13.32 vs. DRAD: 6.47 )
Ranked among companies with meaningful Price/Net Cash only.
DRAD' s 10-Year Price/Net Cash Range
Min: 0.68  Med: 2.61 Max: 7.69
Current: 6.47
0.68
7.69
Price/Net Current Asset Value 3.10
DRAD's Price/Net Current Asset Value is ranked higher than
83% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. DRAD: 3.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DRAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.33  Med: 1.68 Max: 3.72
Current: 3.1
0.33
3.72
Price/Tangible Book 2.44
DRAD's Price/Tangible Book is ranked higher than
68% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. DRAD: 2.44 )
Ranked among companies with meaningful Price/Tangible Book only.
DRAD' s 10-Year Price/Tangible Book Range
Min: 0.23  Med: 1.28 Max: 3.01
Current: 2.44
0.23
3.01
Price/Projected FCF 2.11
DRAD's Price/Projected FCF is ranked lower than
52% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. DRAD: 2.11 )
Ranked among companies with meaningful Price/Projected FCF only.
DRAD' s 10-Year Price/Projected FCF Range
Min: 0.98  Med: 2.08 Max: 2.93
Current: 2.11
0.98
2.93
Price/Median PS Value 1.43
DRAD's Price/Median PS Value is ranked lower than
72% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. DRAD: 1.43 )
Ranked among companies with meaningful Price/Median PS Value only.
DRAD' s 10-Year Price/Median PS Value Range
Min: 0.02  Med: 0.98 Max: 2.27
Current: 1.43
0.02
2.27
Price/Graham Number 1.47
DRAD's Price/Graham Number is ranked higher than
64% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. DRAD: 1.47 )
Ranked among companies with meaningful Price/Graham Number only.
DRAD' s 10-Year Price/Graham Number Range
Min: 1.31  Med: 1.85 Max: 10.13
Current: 1.47
1.31
10.13
Earnings Yield (Greenblatt) (%) 6.28
DRAD's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. DRAD: 6.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DRAD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 4.90 Max: 475
Current: 6.28
0.3
475

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FDV.Germany,
Digirad Corp was incorporated in Delaware in 1997. The Company is a developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The business is organized into two reportable segments: Digirad Imaging Solutions (DIS) and Diagnostic Imaging. It is a provider of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through Digirad Imaging Solutions ("DIS") business segment. The Company sells medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products it sells through its Diagnostic Imaging segment. The target market for its products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear and ultrasound diagnostic imaging procedures. The Company sells a line of nuclear imaging cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its product Ergo large-field-of-view imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women's health centers, and cancer centers. Its Cardius XACT SPECT/CT system features a triple-head design and a low dose volume CT attenuation correction methodology, making it possible to perform studies faster with greater interpretation diagnostic confidence. It uses variety of materials, metals and mechanical and electrical components for production of its products. The Company maintain two sales organizations, which operate independently but in cooperation with each other: Diagnostic Imaging sales and DIS sales. The Company's operations comply with an array of federal and state laws and regulations.
» More Articles for DRAD

Headlines

Articles On GuruFocus.com
Top 3 Insider Buys Highlighted by Energy Companies Jul 12 2013 
DRAD Directors Increase Their Stake in the Medical Supply Company Apr 25 2013 
Expansion Initiates Insider Buying for NTS Apr 11 2013 
Digirad Corp. Reports Operating Results (10-K/A) Jul 30 2010 
Digirad Corp. Reports Operating Results (10-Q) Jul 29 2010 
Digirad Corp. Reports Operating Results (10-Q) Apr 29 2010 
Digirad Corporation Q3 2009 update Oct 29 2009 
Miguel Barbosa Interviews Famous Blogger, Greenbackd! Oct 29 2009 
Digirad Corp. Reports Operating Results (10-Q) Oct 22 2009 
Digirad Corporation Reports Fourth Quarter and Full Year 2008 Financial Results Feb 05 2009 

More From Other Websites
Edited Transcript of DRAD earnings conference call or presentation 7-Aug-15 3:00pm GMT Sep 02 2015
Digirad Corp. Q2 Earnings, 2015 Aug 25 2015
DIGIRAD CORP Financials Aug 19 2015
Digirad Corporation to Present at the Midwest Ideas Investor Conference on August 26, 2015 Aug 14 2015
Digirad Corporation to Present at the Midwest Ideas Investor Conference on August 26, 2015 Aug 14 2015
10-Q for Digirad Corp. Aug 09 2015
Digirad Corp Earnings Call scheduled for 11:00 am ET today Aug 07 2015
Q2 2015 Digirad Corp Earnings Release - Before Market Open Aug 07 2015
Digirad posts 2Q profit Aug 07 2015
Digirad posts 2Q profit Aug 07 2015
Digirad Corporation Reports Financial Results for the Second Quarter and Six Months ended June 30,... Aug 07 2015
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2015
Digirad Corporation Reports Financial Results for the Second Quarter and Six Months ended June 30,... Aug 07 2015
DIGIRAD CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 05 2015
Digirad Announces That It Has Completed Its Strategic Partnership and Investment Into Perma-Fix... Jul 27 2015
Digirad Announces That It Has Completed Its Strategic Partnership and Investment Into Perma-Fix... Jul 27 2015
DIGIRAD CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 27 2015
Digirad Corporation to Release 2015 Second Quarter and Six Month Financial Results on August 7, 2015 Jul 21 2015
Digirad Corporation to Release 2015 Second Quarter and Six Month Financial Results on August 7, 2015 Jul 21 2015
Connecture Inc (CNXR), Goodrich Petroleum Corporation (GDP), Digirad Corporation (DRAD) Jumped Last... Jun 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK